To develop a prognostic model for more precise prognosis assessment, APOD and PROC, two ARID1A mutation-associated prognostic immune genes were selected to construct the prognostic model (ARM), which demonstrated satisfactory prognostic predictive ability in TCGA datasets and five independent GC patient cohorts from the GEO database. This evidence concerns the gene ARID1A and gastric cancer.